Clinical Trials
12 trialsNCT07601737 2026-05-22
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT05526924 2026-03-04
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
University of Chicago
Phase 1 Recruiting
NCT06494189 2025-12-29
Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma
West China Hospital
Phase 1 Completed
NCT06804850 2025-11-19
Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC
West China Hospital
Phase 2 Withdrawn
NCT05909904 2025-10-07
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
BeiGene
Phase 2 Active not recruiting
NCT05758389 2025-09-05
Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT05517330 2025-07-31
neoCHANCE-1
West China Hospital
Phase 2 Completed
NCT05516589 2025-05-22
neoCHANCE-2
West China Hospital
Phase 2 Completed
NCT04666688 2025-02-12
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
PureTech
Phase 1/2 Completed
NCT06366945 2024-04-16
Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT05595590 2022-10-27
Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT04814069 2021-03-24
A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma:The POTENTIAL Study
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Unknown